These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 24330245)

  • 1. Letter: dermatological complications with therapy for inflammatory bowel disease--authors' reply.
    Ghosh S; Moran GW
    Aliment Pharmacol Ther; 2014 Jan; 39(2):233-4. PubMed ID: 24330245
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: dermatological complications with therapy for inflammatory bowel disease.
    Mihály E; Székely H; Herszényi L; Wikonkál N; Tulassay Z
    Aliment Pharmacol Ther; 2014 Jan; 39(2):232-3. PubMed ID: 24330244
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: TNFα blockers and psoriasis: a 'reasonable paradox' - the role of TH-17 cells.
    Sartini A; Di Girolamo M; Scarcelli A; Bertani A; Marzi L; Lasagni C; Merighi A; Villa E
    Aliment Pharmacol Ther; 2014 May; 39(10):1244-6. PubMed ID: 24735146
    [No Abstract]   [Full Text] [Related]  

  • 4. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.
    Moran GW; Lim AW; Bailey JL; Dubeau MF; Leung Y; Devlin SM; Novak K; Kaplan GG; Iacucci M; Seow C; Martin L; Panaccione R; Ghosh S
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1002-24. PubMed ID: 24099467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skin side effects of inflammatory bowel disease therapy.
    Torres J; Buche S; Delaporte E; Colombel JF
    Inflamm Bowel Dis; 2013 Apr; 19(5):1086-98. PubMed ID: 23474780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: successful mercaptopurine therapy after azathioprine-related pancreatitis in patients with IBD - authors' reply.
    Hindorf U; Almer S
    Aliment Pharmacol Ther; 2013 Jan; 37(1):162-3. PubMed ID: 23205482
    [No Abstract]   [Full Text] [Related]  

  • 7. Miscellaneous adverse events with biologic agents (excludes infection and malignancy).
    Feuerstein JD; Cheifetz AS
    Gastroenterol Clin North Am; 2014 Sep; 43(3):543-63. PubMed ID: 25110258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Letter: tumour necrosis factor alpha blocker switching--a not so simple pharmacokinetic. Authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2015 Jun; 41(12):1302-3. PubMed ID: 25968154
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure--authors' reply.
    Gisbert JP; Chaparro M
    Aliment Pharmacol Ther; 2016 May; 43(9):1020. PubMed ID: 27040169
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial: methotrexate vs azathioprine-do differential rates of discontinuation settle the debate? Authors' reply.
    Vasudevan A; Con D; Nicolaides S; van Langenberg DR
    Aliment Pharmacol Ther; 2020 Nov; 52(9):1529-1530. PubMed ID: 33263380
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply to Soteriadou et al.
    Dave M; Purohit T; Razonable RR; Loftus EV
    Inflamm Bowel Dis; 2014 Feb; 20(2):E5-6. PubMed ID: 24374883
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter: infliximab therapy for patients with inflammatory bowel disease--some unanswered questions. Authors' reply.
    Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1134. PubMed ID: 26427756
    [No Abstract]   [Full Text] [Related]  

  • 13. Physicians may inadequately counsel inflammatory bowel disease patients about immunosuppressive therapy and risk of nonmelanoma skin cancer.
    Borum ML; Preethi Sidhu H; Bornstein L
    Inflamm Bowel Dis; 2011 May; 17(5):1246. PubMed ID: 21484964
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunosuppressive therapy for chronic inflammatory bowel disease.
    Schölmerich J
    Digestion; 1997; 58 Suppl 1():94-7. PubMed ID: 9225103
    [No Abstract]   [Full Text] [Related]  

  • 15. The "Q" of fever in inflammatory bowel disease.
    Soteriadou S; Blanchard T; Limdi JK
    Inflamm Bowel Dis; 2014 Feb; 20(2):E4-5. PubMed ID: 24374882
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased.
    Peyrin-Biroulet L; Chevaux JB; Bouvier AM; Carrat F; Beaugerie L
    Am J Gastroenterol; 2012 Sep; 107(9):1443-4. PubMed ID: 22951883
    [No Abstract]   [Full Text] [Related]  

  • 17. Azathioprine side effects in the treatment of chronic inflammatory bowel disease.
    González Lara V; Pérez Calle JL
    Rev Esp Enferm Dig; 2001 Dec; 93(12):765-8. PubMed ID: 11995358
    [No Abstract]   [Full Text] [Related]  

  • 18. [Is the risk of lymphoma increased by immunosuppressive therapy in patients with inflammatory bowel disease? The missing link for considering early immunosuppressants].
    Beaugerie L
    Gastroenterol Clin Biol; 2004 Mar; 28(3):218-20. PubMed ID: 15094669
    [No Abstract]   [Full Text] [Related]  

  • 19. Vedolizumab is an effective alternative in inflammatory bowel disease patients with anti-TNF-alpha therapy-induced dermatological side effects.
    Pijls PA; Gilissen LP
    Dig Liver Dis; 2016 Nov; 48(11):1391-1393. PubMed ID: 27639825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of lymphoma: inflammatory bowel disease and immunomodulators.
    Ang YS; Farrell RJ
    Gut; 2006 Apr; 55(4):580-1. PubMed ID: 16531538
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.